Overview

A Prospective, Randomized, Open-Label, Cross-Over Study of Lokelma to Control Interdialytic Hyperkalemia

Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
A Prospective, RanDomized, Multi-Center, Open-Label, Cross-Over Study of Sodium Zirconium Cyclosilicate to Control Interdialytic HyperkalemiA Following Augmentation of Dialysate Potassium: Efficacy to Reduce the Incidence of Post-Dialysis Atrial Fibrillation and Clinically SignificanT Cardiac Arrhythmias - ADAPT Trial
Phase:
Phase 4
Details
Lead Sponsor:
NephroNet, Inc.
Collaborator:
AstraZeneca